Windtree Therapeutics Inc Watch

from 8-K 43 pages At the Market Offering Agreement November 9, 2023

from 8-K 42 pages 3,686,006 Shares of Common Stock, Pre-Funded Warrants Exercisable Into 0 Shares of Common Stock and Common Warrants Exercisable Into 3,686,006 Shares of Common Stock of Windtree Therapeutics, Inc. Underwriting Agreement

from S-1/A 24 pages Shares of Common Stock, Pre-Funded Warrants Exercisable Into Shares of Common Stock and Common Warrants Exercisable Into Shares of Common Stock of Windtree Therapeutics, Inc. Underwriting Agreement

from 8-K 39 pages 9,230,500 Shares of Common Stock, and Warrants Exercisable Into 9,230,500 Shares of Common Stock, and of Windtree Therapeutics, Inc. Underwriting Agreement

from S-3 42 pages At the Market Offering Agreement September 17, 2020

from S-1/A 42 pages [●] Shares of Common Stock and [●] Warrants Exercisable Into [●] Shares of Common Stock of Windtree Therapeutics, Inc. Underwriting Agreement

from S-1/A 39 pages [●] Shares of Common Stock and [●] Warrants Exercisable Into [●] Shares of Common Stock of Windtree Therapeutics, Inc. Underwriting Agreement

from 8-K 38 pages Discovery Laboratories, Inc. 16,333,333 Shares of Common Stock Pre-Funded Warrants to Purchase 42,000,000 Shares of Common Stock and Warrants to Purchase 58,333,333 Shares of Common Stock Underwriting Agreement

from 8-K 36 pages 25,000,000 Shares Discovery Laboratories, Inc. Common Stock Underwriting Agreement October 31, 2013

from 8-K 29 pages 9,500,000 Shares Discovery Laboratories, Inc. Common Stock Underwriting Agreement May 10, 2013

from 8-K 44 pages 16,071,429 Firm Shares of Common Stock 2,410,714 Over-Allotment Shares Discovery Laboratories, Inc. Common Stock (Par Value $0.001) Underwriting Agreement

from 8-K 41 pages 10,000,000 Units Discovery Laboratories, Inc. Common Stock (Par Value $0.001) Underwriting Agreement

from 8-K 43 pages 35,714,286 Units Discovery Laboratories, Inc. Common Stock (Par Value $0.001) Underwriting Agreement

from 8-K 10 pages Securities Purchase Agreement

from 8-K 2 pages Third Amended and Restated Promissory Note

from 8-K 11 pages Payment Agreement and Loan Amendment

from 8-K 41 pages 27,500,000 Units Discovery Laboratories, Inc. Common Stock (Par Value $0.001) Underwriting Agreement

from 8-K 19 pages Discovery Laboratories, Inc. 2007 Long-Term Incentive Plan

from 8-K ~50 pages Underwriting agreement

from SC 13G/A 1 page Exhibit 1.1 Joint Filing Agreement the Undersigned Hereby Agree That the Statement on This Schedule 13g/A, Dated June 12, 2003, (The "Schedule 13g/A"), With Respect to the Common Stock, Par Value $0.001 Per Share, of Discovery Laboratories, Inc. Is Filed on Behalf of Each of US Pursuant to and in Accordance With the Provisions of Rule 13d-1(k) Under the Securities and Exchange Act of 1934, as Amended, and That This Agreement Shall Be Included as an Exhibit to This Schedule 13g/A. Each of the Undersigned Agrees to Be Responsible for the Timely Filing of the Schedule 13g/A, and for the Completeness and Accuracy of the Information Concerning Itself Contained Therein. This Agreement May Be Executed in Any Number of Counterparts, All of Which Taken Together Shall Constitute One and the Same Instrument. in Witness Whereof, the Undersigned Have Executed This Agreement as of the 12th Day of June, 2003. Orbimed Advisors LLC By: /S/ Samuel D. Isaly Name: Samuel D. Isaly Title: Managing Member Orbimed Capital LLC By: /S/ Samuel D. Isaly Name: Samuel D. Isaly Title: Managing Member By: /S/ Samuel D. Isaly Name: Samuel D. Isaly